首页 » 文章 » 文章详细信息
The Scientific World Journal Volume 2020 ,2020-03-31
Effect of Vitamin D Analogue on Rosuvastatin-Induced Myopathy in Wistar Rats
Research Article
Bharti Chogtu 1 Balaji Ommurugan 2 Sereen R. Thomson 3 Sneha G. Kalthur 4
Show affiliations
DOI:10.1155/2020/4704825
Received 2019-11-12, accepted for publication 2020-03-03, Published 2020-03-31
PDF
摘要

Objectives. Statin-induced myopathy is one of the major causes of poor adherence and discontinuation of this medication. There are contrary results regarding association of vitamin D insufficiency with statin-induced myopathy. This study was done to determine the effect of the vitamin D3 analogue alfacalcidol on Rosuvastatin-induced myopathy in rats. Methodology. Animals were divided into six groups with 6 rats in each group. Groups I and II acted as controls, Group III and Group IV were administered Rosuvastatin 120 mg/kg/day and 160 mg/kg/day, Groups V and VI were administered alfacalcidol 0.1 μg/kg/day in addition to Rosuvastatin 120 mg/kg/day and 160 mg/kg/day, respectively. All drugs were administered orally for 15 days. Plasma creatine kinase (CK) levels were estimated on day 10 and day 15. Animals were sacrificed and muscles were sent for histopathological examination. Results. On day 10, Groups V and VI showed a statistically significant increase in plasma CK levels as compared to the control (p0.05). On comparing the histology, Groups V and VI showed a significant difference as compared to statin-only groups (Groups III and IV) as there were signs of regeneration, less splitting, and fragmentation of muscle fibres. Conclusion. The present study shows that the vitamin D analogue alfacalcidol prevents statin-induced myopathy. The serum CK levels are comparable to the control group on day 15 of vitamin D administration.

授权许可

Copyright © 2020 Bharti Chogtu et al. 2020
This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

通讯作者

Bharti Chogtu.Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India, manipal.edu.bharti.magazine@manipal.edu

推荐引用方式

Bharti Chogtu,Balaji Ommurugan,Sereen R. Thomson,Sneha G. Kalthur. Effect of Vitamin D Analogue on Rosuvastatin-Induced Myopathy in Wistar Rats. The Scientific World Journal ,Vol.2020(2020)

您觉得这篇文章对您有帮助吗?
分享和收藏
0

是否收藏?

参考文献
[1] S. Ahmed, E. A. Saber, A. H. Hamouda, R. A. Rifaai. et al.(2017). Structural changes in the skeletal muscle fiber of adult male albino rat following atorvastatin treatment; the possible mechanisms of atorvastatin induced myotoxicity. Journal of Cytology and Histology.8:442. DOI: 10.1161/01.cir.0000131517.20177.5a.
[2] R. P. Gupta, Y. A. He, K. S. Patrick, J. R. Halpert. et al.(2005). CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. The Journal of Clinical Endocrinology & Metabolism.90(2):1210-1219. DOI: 10.1161/01.cir.0000131517.20177.5a.
[3] P. Lee, J. R. Greenfield, L. V. Campbell. (2009). Vitamin D insufficiency—a novel mechanism of statin-induced myalgia?. Clinical Endocrinology.71(1):154-155. DOI: 10.1161/01.cir.0000131517.20177.5a.
[4] R. Deichmann, C. Lavie, S. Andrews. (2010). Coenzyme q10 and statin-induced mitochondrial dysfunction. The Ochsner Journal.10(10):16-21. DOI: 10.1161/01.cir.0000131517.20177.5a.
[5] J. Schwartz. (2009). Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clinical Pharmacology & Therapeutics.85(2):198-203. DOI: 10.1161/01.cir.0000131517.20177.5a.
[6] New Zealand Guidelines Group. (2003). The assessment and management of cardiovascular risk—best practice evidence-based guideline. . DOI: 10.1161/01.cir.0000131517.20177.5a.
[7] G. P. S. Shantha, J. Ramos, L. Thomas-Hemak, S. B. Pancholy. et al.(2014). Association of vitamin D and incident statin induced myalgia--a retrospective cohort study. PLoS One.9(2). DOI: 10.1161/01.cir.0000131517.20177.5a.
[8] M. Banach, T. Stulc, R. Dent, P. P. Toth. et al.(2016). Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. International Journal of Cardiology.225:184-196. DOI: 10.1161/01.cir.0000131517.20177.5a.
[9] D. Kurnik, I. Hochman, J. Vesterman-Landes. (2012). Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins. Clinical Endocrinology.77(1):36-41. DOI: 10.1161/01.cir.0000131517.20177.5a.
[10] D. M. Muntean, P. D. Thompson, A. L. Catapano. (2017). Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?. Drug Discovery Today.22(1):85-96. DOI: 10.1161/01.cir.0000131517.20177.5a.
[11] M.-L. Ovesjö, I. Skilving, P. Bergman, A. Rane. et al.(2016). Low vitamin D levels and genetic polymorphism in the vitamin D receptor are associated with increased risk of statin-induced myopathy. Basic & Clinical Pharmacology & Toxicology.118(3):214-218. DOI: 10.1161/01.cir.0000131517.20177.5a.
[12] K. Manoj, N. Jain, S. V. Madhu. (2017). Myopathy in patients taking atorvastatin: a pilot study. Indian Journal of Endocrinology and Metabolism.21(4):504-509. DOI: 10.1161/01.cir.0000131517.20177.5a.
[13] A. Eisen, E. Lev, Z. Iakobishvilli. (2014). Low Plasma vitamin D levels and muscle-related adverse effects in statin users. The Israel Medical Association Journal : IMAJ.16(16):42-45. DOI: 10.1161/01.cir.0000131517.20177.5a.
[14] M. Lańcut, B. Jedrych, M. Lis-Sochocka, K. Czerny. et al.(2004). Histological and ultrastructural changes in cross-striation muscle cells, under the influence of atorvastatin-reductase HMG-CoA inhibitor. Annales Universitatis Mariae Curie-Sklodowska.59(2):32-37. DOI: 10.1161/01.cir.0000131517.20177.5a.
[15] K. B. Hoffman, C. Kraus, M. Dimbil, B. A. Golomb. et al.(2012). A survey of the FDA’s AERS database regarding muscle and tendon adverse events linked to the statin drug class. PloS One.7(8). DOI: 10.1161/01.cir.0000131517.20177.5a.
[16] A. A. S. Carvalho, Üima. S. Lima, R. A. Valiente. (2004). Statin and fibrate associed myopathy: study of eight patients. Arquivos de neuro-psiquiatria.62(2):257-261. DOI: 10.1161/01.cir.0000131517.20177.5a.
[17] M. F. R. M A. Shuhaili, I. N. Samsudin, J. Stanslas, S. Hasan. et al.(2017). Effects of different types of statins on lipid profile: a perspective on asians. International Journal of Endocrinology and Metabolism.15(15). DOI: 10.1161/01.cir.0000131517.20177.5a.
[18] A. Draeger, K. Monastyrskaya, M. Mohaupt. (2006). Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. The Journal of Pathology.210(1):94-102. DOI: 10.1161/01.cir.0000131517.20177.5a.
[19] M. E. Soliman, S. E. Atteia, M. A. Kefafy, A. F. Ali. et al.(2017). Histological study on the effect of rosuvastatin (Crestor) on the skeletal muscle of adult male albino rats and the possible protective effect of coenzyme Q10. Menoufia Medical Journal.30:1117-1124. DOI: 10.1161/01.cir.0000131517.20177.5a.
[20] K. D. Riche, J. Arnall, K. Rieser, H. E. East. et al.(2016). Impact of vitamin D status on statin-induced myopathy. Journal of Clinical & Translational Endocrinology.6:56-59. DOI: 10.1161/01.cir.0000131517.20177.5a.
[21] N. C. Ward, G. F. Watts, R. H. Eckel. (2019). Statin toxicity. Circulation Research.124(2):328-350. DOI: 10.1161/01.cir.0000131517.20177.5a.
[22] J. M. Backes, B. J. Barnes, J. F. Ruisinger, P. M. Moriarty. et al.(2011). A comparison of 25-hydroxyvitamin D serum levels among those with or without statin-associated myalgias. Atherosclerosis.218(1):247-249. DOI: 10.1161/01.cir.0000131517.20177.5a.
[23] H. Obayashi, Y. Nezu, H. Yokota. (2011). Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats. The Journal of Toxicological Sciences.36(4):445-452. DOI: 10.1161/01.cir.0000131517.20177.5a.
[24] I. J. Riphagen, E. van der Veer, F. A. J. Muskiet, M. J. L. DeJongste. et al.(2012). Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Current Medical Research and Opinion.28(7):1247-1252. DOI: 10.1161/01.cir.0000131517.20177.5a.
[25] J. Davignon. (2004). Beneficial cardiovascular pleiotropic effects of statins. Circulation.109(1). DOI: 10.1161/01.cir.0000131517.20177.5a.
[26] A. Gupta, P. D. Thompson. (2011). The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis.215(1):23-29. DOI: 10.1161/01.cir.0000131517.20177.5a.
[27] F. R. Westwood, R. C. Scott, A. M. Marsden, A. Bigley. et al.(2008). Rosuvastatin: characterization of induced myopathy in the rat. Toxicologic Pathology.36(2):345-352. DOI: 10.1161/01.cir.0000131517.20177.5a.
[28] J. Beltowski, G. Wojcicka, A. Jamroz-Wisniewska. (2009). Adverse effects of statins - mechanisms and consequences. Current Drug Safety.4(3):209-228. DOI: 10.1161/01.cir.0000131517.20177.5a.
[29] J. L. Pérez-Castrillón, L. Abad Manteca, G. Vega, J. Del Pino Montes. et al.(2010). Vitamin D levels and lipid response to atorvastatin. International Journal of Endocrinology.2010. DOI: 10.1161/01.cir.0000131517.20177.5a.
[30] C. Chase. (2004). The pink sheet. FDC Reports.66:31. DOI: 10.1161/01.cir.0000131517.20177.5a.
[31] G. H. Cardinet. (1989). Skeletal muscle function. Clinical Biochemistry of Domestic Animals. DOI: 10.1161/01.cir.0000131517.20177.5a.
[32] T. Y. Morioka, A. J. Lee, S. Bertisch, C. Buettner. et al.(2015). Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study. Atherosclerosis.238(1):77-82. DOI: 10.1161/01.cir.0000131517.20177.5a.
文献评价指标
浏览 24次
下载全文 3次
评分次数 0次
用户评分 0.0分
分享 0次